Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2004
10/12/2004US6803373 Synergistic mixtures; enhanced absorption
10/12/2004US6803363 Peritoneal dialysis solution with taurolidine
10/12/2004US6803057 Hydrogen peroxide disinfectant with increased activity
10/12/2004US6803055 Sustained release; benzazole ring structure; psychological disorders
10/12/2004US6803054 Forming tablets from mixture of drug and sugar; dissolving in mouth
10/12/2004US6803053 Condensed nucleic acid/lipid complex for increasing shelf life and high transfection activity in vivo following intravenous injection
10/12/2004US6803052 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
10/12/2004US6803046 Containing stabilizer, solubilizer, chelator, bulking agent, tonicity adjuster and buffer; fewer degradants; consistent potency
10/12/2004US6803031 Aerosol comprises particles comprising at least 10 percent by weight of an erectile dysfunction drug, such as sildenafil, tadalafil or vardenafil.
10/12/2004CA2170394C Process for conditioning substances
10/12/2004CA2128783C Injectable ceramic compositions and methods for their preparation and use
10/07/2004WO2004086412A2 Radiation protection by gamma-tocotrienol
10/07/2004WO2004085500A1 Polymeric modifiers and pharmaceutical compositions
10/07/2004WO2004085487A1 Novel cyclodextrin derivatives
10/07/2004WO2004085471A2 Glp-2 derivatives
10/07/2004WO2004085386A2 Heterobifunctional polymeric bioconjugates
10/07/2004WO2004084950A2 Cell targeting methods and compositions
10/07/2004WO2004084949A2 Generating protein pro-drugs using reversible ppg linkages
10/07/2004WO2004084948A1 Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
10/07/2004WO2004084947A1 Pharmaceutical composition comprising fungal cell or fragment thereof
10/07/2004WO2004084908A1 Prostaglandin compositions for the treatment of erectile dysfunction
10/07/2004WO2004084900A1 Topical formulation and use of buspirone
10/07/2004WO2004084883A1 Complexes of isotretinoin with natural beta or gamma-cyclodextrin
10/07/2004WO2004084878A1 Compositions and methods for treatment of premature ejaculation
10/07/2004WO2004084877A1 Composition for ophthalmic use
10/07/2004WO2004084861A2 Angiogenesis promotion by prostaglandin compositions and methods
10/07/2004WO2004084859A2 Nasal calcitonin formulations containing chlorobutanol
10/07/2004WO2004084839A2 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
10/07/2004WO2004084826A2 Antifungal nail coat and method of use
10/07/2004WO2004084807A2 Micro-cluster compositions
10/07/2004WO2004084641A1 Use of sweetener acids for the microbiological stabilisation of foodstuffs, cosmetic products, consumer goods and pharmaceutical products
10/07/2004WO2004075919A3 Compounds for protein stabilization and methods for their use
10/07/2004WO2004069171A3 Novel compounds for the treatment of sickle cell disease
10/07/2004WO2004066908A3 Composition containing cationic lipids and a polynucleotide or a polypeptide and method for the targeted delivery of active substances
10/07/2004WO2004060965A3 Hydrolytically stable maleimide-terminated polymers
10/07/2004WO2004060384A3 Pharmaceutical botulinum toxin compositions
10/07/2004WO2004060345A3 Dispersible pharmaceutical compositions
10/07/2004WO2004047729B1 Composition for the prevention and treatment of inflammation of the ear
10/07/2004WO2004041243A3 Stable amorphous celecoxib composite and process therefor
10/07/2004WO2004037316A3 Nanoparticle delivery system
10/07/2004WO2004021999A3 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
10/07/2004WO2004020623B1 Method for producing biodegradable, functionalised polymer particles, and use of the same as medicament carriers
10/07/2004WO2004014350A3 Polymer conjugates of a local anaesthetic drug
10/07/2004WO2004013303A3 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
10/07/2004WO2004004757A8 Treatment for eye disorder
10/07/2004WO2004002402A3 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
10/07/2004WO2003090697A3 Chimeric hybrid analgesics
10/07/2004WO2003074027A8 Self emulsifying drug delivery systems for poorly soluble drugs
10/07/2004WO2003059942A3 Peptides and peptidomimetics having anti-proliferative activity and their use
10/07/2004WO2002068451A3 Sperm protein 17 for the diagnosis and treatment of cancer
10/07/2004US20040198949 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
10/07/2004US20040198901 Random block copolymers
10/07/2004US20040198843 mixture of hydrophobic and polarity moiety; high pressure homogenization of crude oil and water
10/07/2004US20040198838 Administering by mouth; side effect reduction; multilayer coating on tablet; fungicides
10/07/2004US20040198829 Adjust transportation of active material to eye
10/07/2004US20040198820 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
10/07/2004US20040198812 Pseudopolymorphic forms of carvedilol
10/07/2004US20040198709 Compositions and methods for enhancing corticosteroid delivery
10/07/2004US20040198706 active agent (not testosterone alone ) and a delivery vehicle containing an alkanol, a polyalcohol, and a permeation enhancer to provide permeation enhancement of the active mammalian dermal or mucosal surface; free of long chain fatty acid, fatty ester and fatty alcohol to avoid odor and irritation
10/07/2004US20040198704 Compositions and method for treating microbial and parasitic infections in cattle and other animals
10/07/2004US20040198699 Composition and method for the treatment of dysglucaemia
10/07/2004US20040198698 Nitrate ester-cyclodextrin complexes
10/07/2004US20040198688 for treatment of atopic conditions (dermatitis, allergies); point mutations
10/07/2004US20040198682 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
10/07/2004US20040198673 Composition for epigallocatechin gallate
10/07/2004US20040198662 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; anticholesterol agents; hypercholesterolemia, cardiovascular disorders, atherosclerosis, restenosis, hypertriglyceridemia, high density lipoprotein deficiency, metabolic disorders
10/07/2004US20040198645 Pharmaceutical compositions
10/07/2004US20040198644 Integrin inhibitors for the treatment of eye diseases
10/07/2004US20040198641 Hydrophobic core coupled to plurality of hydrophilic moieties that form micelles in solution; encapsulate lipoproteins; atherosclerosis; cardiovascular disorders
10/07/2004US20040198639 Mixture with non-formaldehyde preservative; microbiocides; chemical resistance; drugs, medical equipment, cosmetics; antiaging, wrinkle resistance; skin disorders
10/07/2004US20040198638 Administering docetaxel or paclitaxel derivative conjugated to polyglutamic acid, polyaspartic acid, or polylysine as antitumor or anticarcinogenic agent; radiation; autoimmune disorders, rheumatoid arthritis; coatings of stents for prevention of restenosis
10/07/2004US20040198164 Manikin and eye device apparatus, methods and articles of manufacture
10/07/2004US20040197809 Immunoglobulin fusion for prevention or treatment of viral infection; immunotherapy
10/07/2004US20040197502 Heat generating article
10/07/2004US20040197469 Apparatus and method for preparing microparticles
10/07/2004US20040197417 Having a reduced level of residual solvent(s); controlled-release microparticles having improved shelf-life
10/07/2004US20040197416 contains dehydroepiandrosterone (DHEA) or its derivatives, aqueous medium, a polymer shell and a lipid core containing an oily solvent
10/07/2004US20040197414 Controllably dissolvable silica-xerogels prepared via sol-gel process; delivery device including the silica-xerogel into which structure a biologically active agent is incorporated; drugs; Medical devices for orthopedic and surgical purposes
10/07/2004US20040197410 uniformly contains pullulan and a non-reducing saccharide(s) composed of glucose units, has an improved rate of water dissolution, and retains a satisfactory resistance to humidity; culturing a microorganism capable of producing pullulan followed by purification
10/07/2004US20040197408 Amino acids in micelle preparation
10/07/2004US20040197405 Multiparticulate modified release composition
10/07/2004US20040197404 Extended release oral dosage form
10/07/2004US20040197402 Oxcarbazepine dosage forms
10/07/2004US20040197393 sandwich liposome comprises one or more biologically active agents internalized between two bilomellar liposomes; (1,2-bis(oleoyloxy)-3-(trimethylammonio)-propane) and cholesterol and a nucleic acid
10/07/2004US20040197392 comprising 1-acyl-2-acyl-glycero-3-phosphoethanolamine and 1-acyl-2-acylsuccinylglycerol or 1-acyl-3-acylsuccinylglycerol; identification of a tumour, inflammation or cardiac infarct tissue in a human or non-human animal; Magnetic Resonance imaging
10/07/2004US20040197391 Stable topical drug delivery compositions
10/07/2004US20040197381 Enteral nutrition product and method for preparing the same
10/07/2004US20040197379 Foods; viscosity lowering polysaccharides; maltodextrin-glucomannan complex; supplying fiber to diabetic individuals
10/07/2004US20040197369 Mixing active drug with macromer; polymerization
10/07/2004US20040197368 Surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents
10/07/2004US20040197360 Hybrid composite dispersion; polycarbonateether block copolymer in aqueous solution
10/07/2004US20040197358 8-tetradecenal serving as an odorous or aromatic substance
10/07/2004US20040197340 Pharmaceutical composition based on macrolides for topical application in ophthalmology
10/07/2004US20040197332 antiproliferative agents; antitumor and anticancer agents; monoclonal antibodies produced by hybridomas cell ling
10/07/2004US20040197328 Screening; separation using cancer cytotoxicity; diagnosis; anticancer, antitumor agents; administering monoclonal antibodies
10/07/2004US20040197324 High concentration antibody and protein formulations
10/07/2004US20040197323 Bioavailability; amidated in situ; adjustment of pH; protective barrier for stomach
10/07/2004US20040197314 gene expression of polypeptide in membrane vesicle ; forming antibodies; controlling immunology response
10/07/2004US20040197302 Positioning in mammalian body ; solidification when exposured to trigger
10/07/2004US20040197294 Cosmetic and/or pharmaceutical preparations